FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Neil Osheroff

Research Profile

Chemicals & Drugs

Disorders

DNA Damage

Concepts & Ideas

Co-author Network

Publications

TOP 3
Katie J Aldred; Robert J Kerns; Sylvia A McPherson; Charles L Turnbough; Neil Osheroff
Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance.
Steven L Pitts; Michael J Jablonksy; Maria Duca; Daniel Dauzonne; Claude Monneret; Paola B Arimondo; Clemens Anklin; David E Graves; Neil Osheroff
Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
Amanda C Gentry; Sissel Juul; Christopher Veigaard; Birgitta R Knudsen; Neil Osheroff
The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Neil Osheroff (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Katie J Aldred; Robert J Kerns; Sylvia A McPherson; Charles L Turnbough; Neil Osheroff
Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance.
Nucleic acids research 2013;41(8):4628-39.
2011: Steven L Pitts; Michael J Jablonksy; Maria Duca; Daniel Dauzonne; Claude Monneret; Paola B Arimondo; Clemens Anklin; David E Graves; Neil Osheroff
Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
Biochemistry 2011;50(22):5058-66.
2011: Amanda C Gentry; Sissel Juul; Christopher Veigaard; Birgitta R Knudsen; Neil Osheroff
The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I.
Nucleic acids research 2011;39(3):1014-22.
2011: M Joannides; A N Mays; A R Mistry; Neil Osheroff; A Reiter; Ellen Solomon; Joseph L Wiemels; F Lo Coco; C A Felix; Syed Khizer Hasan; David Grimwade
Molecular pathogenesis of secondary acute promyelocytic leukemia.
Mediterranean journal of hematology and infectious diseases 2011;3(1):e2011045.
2010: Ashley N Mays; Neil Osheroff; Yuanyuan Xiao; Joseph L Wiemels; Carolyn A Felix; Jo Ann W Byl; Kandeepan Saravanamuttu; Andrew Peniket; Robert Corser; Cherry Chang; Christine Hoyle; Anne Parker; Syed Khizer Hasan; Francesco Lo Coco; Ellen Solomon; David Grimwade
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.
Blood 2010;115(2):326-30.
2010: Yang Wang; Robert J Coffey; Neil Osheroff; Kristi L Neufeld
Topoisomerase IIalpha binding domains of adenomatous polyposis coli influence cell cycle progression and aneuploidy.
PloS one 2010;5(4):e9994.
2009: Joseph E Deweese; F Peter Guengerich; Alex B Burgin; Neil Osheroff
Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase IIalpha.
Biochemistry 2009;48(38):8940-7.
2009: Joseph E Deweese; Amber M Burch; Alex B Burgin; Neil Osheroff
Use of divalent metal ions in the dna cleavage reaction of human type II topoisomerases.
Biochemistry 2009;48(9):1862-9.
2009: Joseph E Deweese; Neil Osheroff
Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons.
Biochemistry 2009;48(7):1439-41.
2009: Joseph E Deweese; Neil Osheroff
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing.
Nucleic acids research 2009;37(3):738-48.
2009: Omari J Bandele; Neil Osheroff
Cleavage of plasmid DNA by eukaryotic topoisomerase II.
Methods in molecular biology (Clifton, N.J.) 2009;582():39-47.
2008: A Kathleen McClendon; Amanda C Gentry; Jennifer S Dickey; Marie Brinch; Simon Bendsen; Anni H Andersen; Neil Osheroff
Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain.
Biochemistry 2008;47(50):13169-78.
2008: Omari J Bandele; Neil Osheroff
The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.
Biochemistry 2008;47(45):11900-8.
2008: Syed Khizer Hasan; Ashley N Mays; Tiziana Ottone; Antonio Ledda; Giorgio La Nasa; Chiara Cattaneo; Erika Borlenghi; Lorella Melillo; Enrico Montefusco; José Cervera; Christopher Stephen; Gnanam Satchi; Anne Lennard; Marta Libura; Jo Ann W Byl; Neil Osheroff; Sergio Amadori; Carolyn A Felix; Maria Teresa Voso; Wolfgang R Sperr; Jordi Esteve; Miguel A Sanz; David Grimwade; Francesco Lo Coco
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.
Blood 2008;112(8):3383-90.
2008: Yang Wang; Yoshiaki Azuma; David Moore; Neil Osheroff; Kristi L Neufeld
Interaction between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: implication for the G2/M transition.
Molecular biology of the cell 2008;19(10):4076-85.
2008: Joseph E Deweese; Alex B Burgin; Neil Osheroff
Human topoisomerase IIalpha uses a two-metal-ion mechanism for DNA cleavage.
Nucleic acids research 2008;36(15):4883-93.
2008: Omari J Bandele; Sara J Clawson; Neil Osheroff
Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement.
Chemical research in toxicology 2008;21(6):1253-60.
2008: Ryan P Bender; Michael J Jablonksy; Mohammad Shadid; Ian Romaine; Norma Dunlap; Clemens Anklin; David E Graves; Neil Osheroff
Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.
Biochemistry 2008;47(15):4501-9.
2008: Joseph E Deweese; Alex B Burgin; Neil Osheroff
Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha.
Biochemistry 2008;47(13):4129-40.
2008: Omari J Bandele; Neil Osheroff
(-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases.
Chemical research in toxicology 2008;21(4):936-43.
2008: Blaine W Robinson; Nai-Kong V Cheung; Christos P Kolaris; Suresh C Jhanwar; John K Choi; Neil Osheroff; Carolyn A Felix
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome.
Blood 2008;111(7):3802-12.
2008: Piotr P Pilarski; D Alan Johnstone; Cathleen C Pettepher; Neil Osheroff
From music to macromolecules: using rich media/podcast lecture recordings to enhance the preclinical educational experience.
Medical teacher 2008;30(6):630-2.
2007: A Kathleen McClendon; Neil Osheroff
DNA topoisomerase II, genotoxicity, and cancer.
Mutation research 2007;623(1-2):83-97.
2007: Amy M Wilstermann; Ryan P Bender; Murrell Godfrey; Sungjo Choi; Clemens Anklin; David B Berkowitz; Neil Osheroff; David E Graves
Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.
Biochemistry 2007;46(28):8217-25.
2007: Ryan P Bender; Neil Osheroff
Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.
Chemical research in toxicology 2007;20(6):975-81.
2007: Omari J Bandele; Neil Osheroff
Bioflavonoids as poisons of human topoisomerase II alpha and II beta.
Biochemistry 2007;46(20):6097-108.
2007: Ryan P Bender; Amy-Joan L Ham; Neil Osheroff
Quinone-induced enhancement of DNA cleavage by human topoisomerase IIalpha: adduction of cysteine residues 392 and 405.
Biochemistry 2007;46(10):2856-64.
2007: Rikke From Frøhlich; Christopher Veigaard; Félicie Faucon Andersen; A Kathleen McClendon; Amanda C Gentry; Anni H Andersen; Neil Osheroff; Tinna Stevnsner; Birgitta R Knudsen
Tryptophane-205 of human topoisomerase I is essential for camptothecin inhibition of negative but not positive supercoil removal.
Nucleic acids research 2007;35(18):6170-80.
2006: Neil Osheroff
Unraveling the structure of the variola topoisomerase IB-DNA complex: a possible new twist on smallpox therapy.
Molecular interventions 2006;6(5):245-8.
2006: A Kathleen McClendon; Jennifer S Dickey; Neil Osheroff
Ability of viral topoisomerase II to discern the handedness of supercoiled DNA: bimodal recognition of DNA geometry by type II enzymes.
Biochemistry 2006;45(38):11674-80.
2006: Ryan P Bender; Hans-Joachim Lehmler; Larry W Robertson; Gabriele Ludewig; Neil Osheroff
Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIalpha: altering enzyme function by blocking the N-terminal protein gate.
Biochemistry 2006;45(33):10140-52.
2006: A Kathleen McClendon; Neil Osheroff
The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.
Biochemistry 2006;45(9):3040-50.
2005: A Kathleen McClendon; A Chapin Rodriguez; Neil Osheroff
Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks.
The Journal of biological chemistry 2005;280(47):39337-45.
2005: Jennifer S Dickey; James L Van Etten; Neil Osheroff
DNA methylation impacts the cleavage activity of Chlorella virus topoisomerase II.
Biochemistry 2005;44(46):15378-86.
2005: Jennifer S Dickey; Neil Osheroff
Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.
Biochemistry 2005;44(34):11546-54.
2005: E L Baldwin; Neil Osheroff
Etoposide, topoisomerase II and cancer.
Current medicinal chemistry. Anti-cancer agents 2005;5(4):363-72.
2005: R Hunter Lindsey; Ryan P Bender; Neil Osheroff
Stimulation of topoisomerase II-mediated DNA cleavage by benzene metabolites.
Chemico-biological interactions 2005;153-154():197-205.
2005: R Hunter Lindsey; Ryan P Bender; Neil Osheroff
Effects of benzene metabolites on DNA cleavage mediated by human topoisomerase II alpha: 1,4-hydroquinone is a topoisomerase II poison.
Chemical research in toxicology 2005;18(4):761-70.
2005: Renier Vélez-Cruz; James N Riggins; J Scott Daniels; Hongliang Cai; F Peter Guengerich; Lawrence J Marnett; Neil Osheroff
Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells.
Biochemistry 2005;44(10):3972-81.
2005: Jennifer S Dickey; Tae-Jin Choi; James L Van Etten; Neil Osheroff
Chlorella virus Marburg topoisomerase II: high DNA cleavage activity as a characteristic of Chlorella virus type II enzymes.
Biochemistry 2005;44(10):3899-908.
2005: E L Baldwin; Adam C Berger; Anita H Corbett; Neil Osheroff
Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II.
Nucleic acids research 2005;33(3):1021-30.
2004: Kenneth Bromberg; Renier Vélez-Cruz; Alex B Burgin; Neil Osheroff
DNA ligation catalyzed by human topoisomerase II alpha.
Biochemistry 2004;43(42):13416-23.
2004: R Hunter Lindsey; Kenneth Bromberg; Carolyn A Felix; Neil Osheroff
1,4-Benzoquinone is a topoisomerase II poison.
Biochemistry 2004;43(23):7563-74.
2004: Ryan P Bender; R Hunter Lindsey; D Andrew Burden; Neil Osheroff
N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison.
Biochemistry 2004;43(12):3731-9.
2004: Neil Osheroff
Diflomotecan. Ipsen.
IDrugs : the investigational drugs journal 2004;7(3):257-63.
2004: Erin L Baldwin; Jo Ann Wilson Byl; Neil Osheroff
Cobalt enhances DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells.
Biochemistry 2004;43(3):728-35.
2004: Darshan S Sappal; A Kathleen McClendon; James A Fleming; Vala Thoroddsen; Kelly Connolly; Corinne Reimer; Ronald K Blackman; Christine E Bulawa; Neil Osheroff; Peter Charlton; Laura A Rudolph-Owen
Biological characterization of MLN944: a potent DNA binding agent.
Molecular cancer therapeutics 2004;3(1):47-58.
2003: Michelle Sabourin; John L. Nitiss; Karin C Nitiss; Kazuo Tatebayashi; Hideo Ikeda; Neil Osheroff
Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.
Nucleic acids research 2003;31(15):4373-84.
2003: Kenneth Bromberg; Alex B Burgin; Neil Osheroff
Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Biochemistry 2003;42(12):3393-8.
2003: Kenneth Bromberg; Alex B Burgin; Neil Osheroff
A two-drug model for etoposide action against human topoisomerase IIalpha.
The Journal of biological chemistry 2003;278(9):7406-12.
2003: Amy M Wilstermann; Neil Osheroff
Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
Current topics in medicinal chemistry 2003;3(3):321-38.
2002: John M Fortune; Jennifer S Dickey; Oleg V Lavrukhin; James L Van Etten; R Stephen Lloyd; Neil Osheroff
Site-specific DNA cleavage by Chlorella virus topoisomerase II.
Biochemistry 2002;41(39):11761-9.
2002: Kenneth Bromberg; Chris Hendricks; Alex B Burgin; Neil Osheroff
Human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5' covalently activated oligonucleotide substrates to study enzyme mechanism.
The Journal of biological chemistry 2002;277(34):31201-6.
2001: Amy M Wilstermann; Neil Osheroff
Base excision repair intermediates as topoisomerase II poisons.
The Journal of biological chemistry 2001;276(49):46290-6.
2001: Kenneth Bromberg; Neil Osheroff
DNA cleavage and religation by human topoisomerase II alpha at high temperature.
Biochemistry 2001;40(28):8410-8.
2001: John M Fortune; Oleg V Lavrukhin; James R Gurnon; James L Van Etten; R Stephen Lloyd; Neil Osheroff
Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity.
The Journal of biological chemistry 2001;276(26):24401-8.
2001: Amy M Wilstermann; Neil Osheroff
Positioning the 3'-DNA terminus for topoisomerase II-mediated religation.
The Journal of biological chemistry 2001;276(21):17727-31.
2001: VE Anderson; Neil Osheroff
Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.
Current pharmaceutical design 2001;7(5):337-53.
2001: Jo Ann Wilson Byl; SD Cline; T Utsugi; Takashi Kobunai; Yasuaki Yamada; Neil Osheroff
DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Biochemistry 2001;40(3):712-8.
2001: D Andrew Burden; SJ Froelich-Ammon; Neil Osheroff
Topoisomerase II-mediated cleavage of plasmid DNA.
Methods in molecular biology (Clifton, N.J.) 2001;95():283-9.
2001: John M Fortune; Neil Osheroff
Topoisomerase II-catalyzed relaxation and catenation of plasmid DNA.
Methods in molecular biology (Clifton, N.J.) 2001;95():275-81.
2001: PS Kingma; John M Fortune; Neil Osheroff
Topoisomerase II-catalyzed ATP hydrolysis as monitored by thin-layer chromatography.
Methods in molecular biology (Clifton, N.J.) 2001;95():51-6.
2000: Michelle Sabourin; Neil Osheroff
Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions.
Nucleic acids research 2000;28(9):1947-54.
2000: Lotte Bjergbaek; PS Kingma; I S Nielsen; Y Wang; Ole Westergaard; Neil Osheroff; Anni H Andersen
Communication between the ATPase and cleavage/religation domains of human topoisomerase IIalpha.
The Journal of biological chemistry 2000;275(17):13041-8.
2000: VE Anderson; RP Zaniewski; Frank S Kaczmarek; Thomas D Gootz; Neil Osheroff
Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Biochemistry 2000;39(10):2726-32.
2000: Oleg V Lavrukhin; John M Fortune; Thomas G Wood; DE Burbank; James L Van Etten; Neil Osheroff; R Stephen Lloyd
Topoisomerase II from Chlorella virus PBCV-1. Characterization of the smallest known type II topoisomerase.
The Journal of biological chemistry 2000;275(10):6915-21.
2000: Lars H Jensen; Karin C Nitiss; A Rose; J Dong; J Zhou; T Hu; Neil Osheroff; Peter B Jensen; Maxwell Sehested; John L. Nitiss
A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.
The Journal of biological chemistry 2000;275(3):2137-46.
2000: John M Fortune; Neil Osheroff
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
Progress in nucleic acid research and molecular biology 2000;64():221-53.
1999: VE Anderson; RP Zaniewski; Frank S Kaczmarek; Thomas D Gootz; Neil Osheroff
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
The Journal of biological chemistry 1999;274(50):35927-32.
1999: John M Fortune; L Velea; David E Graves; T Utsugi; Yasuaki Yamada; Neil Osheroff
DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Biochemistry 1999;38(47):15580-6.
1999: Jo Ann Wilson Byl; John M Fortune; D Andrew Burden; John L. Nitiss; T Utsugi; Yasuaki Yamada; Neil Osheroff
DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Biochemistry 1999;38(47):15573-9.
1999: SD Cline; WR Jones; Michael P Stone; Neil Osheroff
DNA abasic lesions in a different light: solution structure of an endogenous topoisomerase II poison.
Biochemistry 1999;38(47):15500-7.
1999: SD Cline; Neil Osheroff
Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes.
The Journal of biological chemistry 1999;274(42):29740-3.
1999: Paul S. Shapiro; Anne M Whalen; NS Tolwinski; J Wilsbacher; SJ Froelich-Ammon; M Garcia; Neil Osheroff; Natalie G Ahn
Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation.
Molecular and cellular biology 1999;19(5):3551-60.
1999: PS Kingma; D Andrew Burden; Neil Osheroff
Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Biochemistry 1999;38(12):3457-61.
1999: D Andrew Burden; Neil Osheroff
In vitro evolution of preferred topoisomerase II DNA cleavage sites.
The Journal of biological chemistry 1999;274(8):5227-35.
1999: SJ Froelich-Ammon; PS Kingma; Neil Osheroff
Purification of DNA topoisomerase II from Drosophila melanogaster.
Methods in molecular biology (Clifton, N.J.) 1999;94():199-212.
1998: Michelle Sabourin; Jo Ann Wilson Byl; S E Hannah; John L. Nitiss; Neil Osheroff
A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP.
The Journal of biological chemistry 1998;273(44):29086-92.
1998: Neil Osheroff
DNA topoisomerases.
Biochimica et biophysica acta 1998;1400(1-3):1-2.
1998: PS Kingma; Neil Osheroff
The response of eukaryotic topoisomerases to DNA damage.
Biochimica et biophysica acta 1998;1400(1-3):223-32.
1998: D Andrew Burden; Neil Osheroff
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme.
Biochimica et biophysica acta 1998;1400(1-3):139-54.
1998: PS Kingma; Neil Osheroff
Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing. Abasic lesions as a tool to dissect enzyme mechanism.
The Journal of biological chemistry 1998;273(29):17999-8002.
1998: VE Anderson; Thomas D Gootz; Neil Osheroff
Topoisomerase IV catalysis and the mechanism of quinolone action.
The Journal of biological chemistry 1998;273(28):17879-85.
1998: John M Fortune; Neil Osheroff
Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.
The Journal of biological chemistry 1998;273(28):17643-50.
1998: John L. Nitiss; J Zhou; A Rose; Y Hsiung; K C Gale; Neil Osheroff
The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.
Biochemistry 1998;37(9):3078-85.
1997: G Marx; H Zhou; David E Graves; Neil Osheroff
Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Biochemistry 1997;36(50):15884-91.
1997: SD Cline; T L Macdonald; Neil Osheroff
Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Biochemistry 1997;36(42):13095-101.
1997: PS Kingma; C A Greider; Neil Osheroff
Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints.
Biochemistry 1997;36(20):5934-9.
1997: PS Kingma; Neil Osheroff
Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage.
The Journal of biological chemistry 1997;272(11):7488-93.
1997: Sarah H Elsea; M Westergaard; D Andrew Burden; J P Lomenick; Neil Osheroff
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Biochemistry 1997;36(10):2919-24.
1997: PS Kingma; Neil Osheroff
Apurinic sites are position-specific topoisomerase II poisons.
The Journal of biological chemistry 1997;272(2):1148-55.
1996: D Andrew Burden; PS Kingma; S J Froelich-Ammon; Mary-Ann Bjornsti; M W Patchan; Richard B Thompson; Neil Osheroff
Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes.
The Journal of biological chemistry 1996;271(46):29238-44.
1995: S J Froelich-Ammon; D Andrew Burden; M W Patchan; Sarah H Elsea; Richard B Thompson; Neil Osheroff
Increased drug affinity as the mechanistic basis for drug hypersensitivity of a mutant type II topoisomerase.
The Journal of biological chemistry 1995;270(47):28018-21.
1995: PS Kingma; Anita H Corbett; P C Burcham; Lawrence J Marnett; Neil Osheroff
Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. DNA lesions as endogenous topoisomerase II poisons.
The Journal of biological chemistry 1995;270(37):21441-4.
1995: S J Froelich-Ammon; Neil Osheroff
Topoisomerase poisons: harnessing the dark side of enzyme mechanism.
The Journal of biological chemistry 1995;270(37):21429-32.
1995: Y Hsiung; Sarah H Elsea; Neil Osheroff; John L. Nitiss
A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
The Journal of biological chemistry 1995;270(35):20359-64.
1995: S J Froelich-Ammon; M W Patchan; Neil Osheroff; Richard B Thompson
Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.
The Journal of biological chemistry 1995;270(25):14998-5004.
1995: Sarah H Elsea; Y Hsiung; John L. Nitiss; Neil Osheroff
A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.
The Journal of biological chemistry 1995;270(4):1913-20.
1994: L H Lin; Linda Van Eldik; Neil Osheroff; Jeanette J Norden
Inhibition of protein kinase C- and casein kinase II-mediated phosphorylation of GAP-43 by S100 beta.
Brain research. Molecular brain research 1994;25(3-4):297-304.
1994: S J Froelich-Ammon; K C Gale; Neil Osheroff
Site-specific cleavage of a DNA hairpin by topoisomerase II. DNA secondary structure as a determinant of enzyme recognition/cleavage.
The Journal of biological chemistry 1994;269(10):7719-25.
1994: Neil Osheroff; Anita H Corbett; M J Robinson
Mechanism of action of topoisomerase II-targeted antineoplastic drugs.
Advances in pharmacology (San Diego, Calif.) 1994;29B():105-26.
1994: Neil Osheroff; Anita H Corbett; Sarah H Elsea; M Westergaard
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S19-25.
1993: Anita H Corbett; P Guerry; P Pflieger; Neil Osheroff
A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential.
Antimicrobial agents and chemotherapy 1993;37(12):2599-605.
1993: Sarah H Elsea; P R McGuirk; Thomas D Gootz; M Moynihan; Neil Osheroff
Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential.
Antimicrobial agents and chemotherapy 1993;37(10):2179-86.
1993: Anita H Corbett; Neil Osheroff
When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs.
Chemical research in toxicology 1993;6(5):585-97.
1993: Anita H Corbett; D Hong; Neil Osheroff
Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
The Journal of biological chemistry 1993;268(19):14394-8.
1993: M J Robinson; Anita H Corbett; Neil Osheroff
Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Biochemistry 1993;32(14):3638-43.
1993: S J Froelich-Ammon; P R McGuirk; Thomas D Gootz; M R Jefson; Neil Osheroff
Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme.
Antimicrobial agents and chemotherapy 1993;37(4):646-51.
1993: Anita H Corbett; A W Fernald; Neil Osheroff
Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation.
Biochemistry 1993;32(8):2090-7.
1992: Anita H Corbett; Russell F DeVore; Neil Osheroff
Effect of casein kinase II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis.
The Journal of biological chemistry 1992;267(28):20513-8.
1992: Sarah H Elsea; Neil Osheroff; John L. Nitiss
Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.
The Journal of biological chemistry 1992;267(19):13150-3.
1992: K C Gale; Neil Osheroff
Intrinsic intermolecular DNA ligation activity of eukaryotic topoisomerase II. Potential roles in recombination.
The Journal of biological chemistry 1992;267(17):12090-7.
1992: Russell F DeVore; Anita H Corbett; Neil Osheroff
Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
Cancer research 1992;52(8):2156-61.
1992: M J Robinson; B A Martin; Thomas D Gootz; P R McGuirk; Neil Osheroff
Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.
Antimicrobial agents and chemotherapy 1992;36(4):751-6.
1992: Anita H Corbett; E L Zechiedrich; Neil Osheroff
A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. A two-site model for enzyme-mediated DNA cleavage.
The Journal of biological chemistry 1992;267(2):683-6.
1991: Anita H Corbett; E L Zechiedrich; R Stephen Lloyd; Neil Osheroff
Inhibition of eukaryotic topoisomerase II by ultraviolet-induced cyclobutane pyrimidine dimers.
The Journal of biological chemistry 1991;266(29):19666-71.
1991: M J Robinson; B A Martin; Thomas D Gootz; P R McGuirk; M Moynihan; J A Sutcliffe; Neil Osheroff
Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
The Journal of biological chemistry 1991;266(22):14585-92.
1991: Neil Osheroff; E L Zechiedrich; K C Gale
Catalytic function of DNA topoisomerase II.
BioEssays : news and reviews in molecular, cellular and developmental biology 1991;13(6):269-73.
1991: M J Robinson; Neil Osheroff
Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.
Biochemistry 1991;30(7):1807-13.
1990: E L Zechiedrich; Neil Osheroff
Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers.
The EMBO journal 1990;9(13):4555-62.
1990: K C Gale; Neil Osheroff
Uncoupling the DNA cleavage and religation activities of topoisomerase II with a single-stranded nucleic acid substrate: evidence for an active enzyme-cleaved DNA intermediate.
Biochemistry 1990;29(41):9538-45.
1990: M J Robinson; Neil Osheroff
Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Biochemistry 1990;29(10):2511-5.
1990: P Ackerman; C V Glover; Neil Osheroff
Stimulation of casein kinase II by epidermal growth factor: relationship between the physiological activity of the kinase and the phosphorylation state of its beta subunit.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(2):821-5.
1989: Anni H Andersen; K Christiansen; E L Zechiedrich; P S Jensen; Neil Osheroff; Ole Westergaard
Strand specificity of the topoisomerase II mediated double-stranded DNA cleavage reaction.
Biochemistry 1989;28(15):6237-44.
1989: E L Zechiedrich; K Christiansen; Anni H Andersen; Ole Westergaard; Neil Osheroff
Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate.
Biochemistry 1989;28(15):6229-36.
1989: Neil Osheroff
Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.
Biochemistry 1989;28(15):6157-60.
1989: P Ackerman; Neil Osheroff
Regulation of casein kinase II activity by epidermal growth factor in human A-431 carcinoma cells.
The Journal of biological chemistry 1989;264(20):11958-65.
1989: Neil Osheroff
Biochemical basis for the interactions of type I and type II topoisomerases with DNA.
Pharmacology & therapeutics 1989;41(1-2):223-41.
1988: P Ackerman; C V Glover; Neil Osheroff
Phosphorylation of DNA topoisomerase II in vivo and in total homogenates of Drosophila Kc cells. The role of casein kinase II.
The Journal of biological chemistry 1988;263(25):12653-60.
1987: Neil Osheroff
Role of the divalent cation in topoisomerase II mediated reactions.
Biochemistry 1987;26(20):6402-6.
1987: Neil Osheroff; E L Zechiedrich
Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form.
Biochemistry 1987;26(14):4303-9.
1985: P Ackerman; C V Glover; Neil Osheroff
Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(10):3164-8.